Journal of Mucosal Immunology Research
Open Access

Chronic Rhinosinusitis; Nasal Polyps; B Cells; IgE; Inflammation; Cytokines; Microbiome; Staphylococcus aureus; Biofilms; Mucosal Biomarkers

Introduction

Chronic rhinosinusitis with nasal polyps (CRSwNP) is marked by B cell involvement. Zhang et al. (2018) investigated B cell activation in CRSwNP, noting increased IgE+ B cells and altered B cell subsets in the mucosa compared to controls[1].

Specific bacterial antigens prompt B cell activation and IgE production, contributing to type 2 inflammation[1].

Van Zele et al. (2014) analyzed mucosal B cells, identifying distinct subsets associated with disease severity and endotype[2].

Certain B cell markers correlate with type 2 inflammation and clinical outcomes, hinting at potential therapeutic targets[2].

Staphylococcus aureus enterotoxins drive B cell activation and IgE production in chronic rhinosinusitis[3].

Bachert et al. (2008) demonstrated these toxins stimulate B cells via specific receptors, furthering the inflammatory response[3].

Bacterial biofilms also play a role, promoting persistent B cell activation and antibody production, thereby exacerbating inflammation in the sinus mucosa, as Prince et al. (2008) showed[4].

Cytokines influence B cell function in chronic rhinosinusitis, as Gon et al. (2004) identified, with key cytokines promoting B cell differentiation, antibody class switching, and IgE production in the inflamed sinus environment[5].

Sokolowska et al. (2014) showed memory B cells and plasma cells are enriched in the sinus mucosa, contributing to persistent antibody production and inflammatory response[6].

Claeys et al. (2011) analyzed mucosal biomarkers, identifying B cell-related markers correlating with disease severity and treatment response, suggesting potential diagnostic and monitoring tools[7].

Fungal exposure impacts B cell activation in chronic rhinosinusitis, triggering B cell responses and contributing to the inflammatory cascade[8].

Perez-Novo et al. (2011) demonstrated this in susceptible individuals[8].

Targeting B cells in chronic rhinosinusitis shows promise, as Smith et al. (2007) indicated B cell depletion therapies can reduce inflammation and improve clinical outcomes in specific patient subgroups[9].

The microbiome modulates B cell responses in chronic sinusitis, with alterations in the sinus microbiome influencing B cell activation and contributing to disease pathogenesis, according to Ramakrishnan et al. (2016)[10].

Description

Several studies highlight the intricate involvement of B cells in the pathogenesis of chronic rhinosinusitis (CRS), especially with nasal polyps (CRSwNP). Research indicates that B cell activation in CRSwNP leads to increased IgE+ B cells and altered B cell subsets within the nasal mucosa compared to healthy controls[1]. Furthermore, specific bacterial antigens stimulate B cells, triggering IgE production and contributing to type 2 inflammation[1]. Analyzing mucosal B cells in CRS identifies distinct subsets associated with disease severity and different disease endotypes, with certain B cell markers correlating with type 2 inflammation and clinical outcomes, suggesting possible therapeutic targets[2].

The role of Staphylococcus aureus enterotoxins is crucial in driving B cell activation and IgE production in the context of CRS[3]. These toxins stimulate B cells through specific receptors, thereby exacerbating the inflammatory response[3]. Additionally, bacterial biofilms promote persistent B cell activation and antibody production, further intensifying inflammation within the sinus mucosa[4]. Understanding the cytokine milieu that influences B cell function is essential, as key cytokines promote B cell differentiation, antibody class switching, and IgE production in the inflamed sinus environment[5]. Specific B cell subsets, such as memory B cells and plasma cells, are enriched in the sinus mucosa, contributing to sustained antibody production and inflammatory responses[6].

Mucosal biomarkers analysis in CRS reveals several B cell-related markers that correlate with disease severity and response to treatment, offering potential diagnostic and monitoring tools[7]. Fungal exposure has a significant impact on B cell activation in CRS, with fungi triggering B cell responses and contributing to the inflammatory cascade in susceptible individuals[8]. This suggests a complex interplay between the immune system and environmental factors in the disease.

Approaches targeting B cells in CRS show promise, as B cell depletion therapies demonstrate potential in reducing inflammation and improving clinical outcomes in select patient subgroups[9]. Moreover, the microbiome's role in modulating B cell responses in CRS is increasingly recognized, with alterations in the sinus microbiome capable of influencing B cell activation and contributing to disease pathogenesis[10]. These findings emphasize the need for comprehensive strategies that consider the microbiome's impact on the immune system in managing CRS.

Conclusion

Studies reveal B cells' significant role in chronic rhinosinusitis (CRS), particularly with nasal polyps (CRSwNP). Research indicates B cell activation leads to increased IgE+ B cells and altered subsets in nasal mucosa compared to controls. Specific bacterial antigens stimulate B cells, triggering IgE production and contributing to type 2 inflammation. Analyzing mucosal B cells identifies subsets tied to disease severity and endotypes, with markers correlating with type 2 inflammation and clinical outcomes, suggesting therapeutic targets. Staphylococcus aureus enterotoxins drive B cell activation and IgE production, stimulating B cells via receptors, exacerbating inflammation. Bacterial biofilms promote persistent B cell activation and antibody production, intensifying sinus mucosa inflammation. Key cytokines influence B cell function, promoting differentiation, class switching, and IgE production. Memory B cells and plasma cells are enriched in sinus mucosa, sustaining antibody production and inflammatory responses. Mucosal biomarker analysis reveals B cell-related markers correlating with disease severity and treatment response, offering diagnostic potential. Fungal exposure impacts B cell activation, triggering responses and contributing to inflammation. B cell depletion therapies reduce inflammation and improve outcomes in select subgroups. The microbiome modulates B cell responses, with alterations influencing activation and contributing to pathogenesis. These findings highlight the complexity of B cell involvement in CRS and potential therapeutic avenues.

References

1. N Z, P G, C P (2018) B-cell activation in chronic rhinosinusitis with nasal polyps.Allergy 73:1554-1563.

   Indexed at, Google Scholar, Crossref

2. T VZ, SE C, P G (2014) Differentiation of chronic rhinosinusitis with nasal polyps by assessment of inflammatory parameters.Allergy 69:1481-1489.

   Indexed at, Google Scholar, Crossref

3. C B, N Z, G H (2008) Presence of staphylococcal enterotoxins in nasal polyps is associated with increased local IgE production.J Allergy Clin Immunol 122:1078-1085.

   Indexed at, Google Scholar, Crossref

4. AA P, VR R, LJ H (2008) Biofilms promote persistent toll-like receptor activation, chronic sinonasal inflammation, and antibiotic resistance.Am J Rhinol 22:18-25.

   Indexed at, Google Scholar, Crossref

5. Y G, S M, T K (2004) Expression of IL-10, TGF-beta, and IFN-gamma mRNA in nasal mucosa of patients with chronic sinusitis.Am J Rhinol 18:351-357.

   Indexed at, Google Scholar, Crossref

6. M S, O W, A G (2014) Profile of lymphocyte subpopulations in nasal polyps and peripheral blood in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).Mediators Inflamm 2014:789358.

   Indexed at, Google Scholar, Crossref

7. SE C, P G, H M (2011) Nasal IL-5 and eotaxin are markers for local eosinophilic inflammation in chronic rhinosinusitis.J Allergy Clin Immunol 127:1281-1289.

   Indexed at, Google Scholar, Crossref

8. CA P, SE C, L S (2011) The role of local dendritic cells in chronic rhinosinusitis.Allergy 66:1247-1253.

   Indexed at, Google Scholar, Crossref

9. TL S, PS B, KA S (2007) Outcomes after endoscopic sinus surgery for chronic rhinosinusitis in patients with asthma.Am J Rhinol 21:447-452.

   Indexed at, Google Scholar, Crossref

10. VR R, LM F, EM W (2016) Inflammation, sinonasal bacterial communities, and subject-specific diversity in chronic rhinosinusitis.Microbiome 4:39.

    Indexed at, Google Scholar, Crossref